|
2005P-0179:
ANDA Suitability for Ribavirin, USP Tablets in a Strength of 500
mg
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
| ACK1
|
| 05/11/2005
|
| 05/11/2005
|
| Federal Government
|
| HFA-305 to Kilpatrick
Stockton LLP
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Jennie C. Butler
|
|
|
|
|
| CP1
|
| 05/10/2005
|
| 05/10/2005
|
| Private Industry
|
| Kilpatrick Stockton
LLP
|
|
|
|
|
|
|
| Table
of Contents
|
|
|
|
|
| Signature:
|
| Jamie L. Greene
|
|
|
|
|
| PAV1
|
| 07/15/2005
|
| 07/15/2005
|
| Device Industry
|
| HFD-600 to Kilpatrick
Stockton LLP
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
| |
|
|
|
|
Top
| Up
Page last updated:
July 25, 2007
|
